Investor Type | Firm |
Type of Fund | Private Equity Fund |
Industries | Software (Web Marketplace Saas..) • IT (& TMT) • Media • Businesses Solutions • FinTech (& Financials services) • Hardware (& Manufacturing) • HealthTech (& Fitness) • Logistics (& Distribution) |
Stages | Expansion, MBO/LBO, Recapitalization, Restructuring, Special Situations |
Investing | Brazil |
Advent do Brasil Consultoria e Participacoes Ltda. is a global private equity investor with a diversified sector expertise, focusing on numerous industries including Software, IT, Media, Business Solutions, FinTech, Hardware, HealthTech, and Logistics. They operate as a Private Equity Fund specializing in Equity investments, particularly targeting opportunities in Expansion, MBO/LBO (Management Buyout/ Leveraged Buyout), Recapitalization, Restructuring, and Special Situations. With headquarters situated at Av. Brig. Faria Lima 3311 9 andar, So Paulo, So Paulo, 04538-133, Brazil, the firm brings a partnership approach to its portfolio companies, aiming to provide more than just capital. They work closely with management teams to drive value creation through strategic direction, operational support, and providing access to resources. Their investment strategy focuses on key sectors where they have deep industry knowledge and a proven track record. The sectors covered include Business & Financial Services, Consumer, Healthcare, Industrial, and Technology. Aside from its sector expertise, Advent do Brasil is committed to responsible investment practices that take into account environmental, social, and governance (ESG) factors. On their global platform, they have a broad reach with offices across various continents, including Australia, Brazil, Colombia, France, Germany, Greater China, India, Italy, Luxembourg, Mexico, Spain, the United Kingdom, and the United States. This allows them to leverage local insights with a global perspective on each investment. They showcase their portfolio successes and provide thought leadership on industry trends, as seen in their 'Ideas' section, where they offer insights on how drug companies can make medicines more effectively.